|Bid||0.0050 x 13220527400|
|Ask||0.0060 x 1678304300|
|Day's range||0.0050 - 0.0060|
|52-week range||0.0040 - 0.0200|
|Beta (5Y monthly)||0.88|
|PE ratio (TTM)||N/A|
|Earnings date||26 Feb 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce the Australian Patent Office ("IP Australia") has granted Australian Patent No. AU 2018210690 to Canntab, related to its proprietary cannabidiol formulations with a priority date of January 23, 2017. The term of the patent expires on January 22, 2038.
It is a pleasure to report that the Cann Global Limited ( ASX:CGB ) is up 83% in the last quarter. But that doesn't...
Sholom Feldman has been the CEO of Cann Global Limited (ASX:CGB) since 2007, and this article will examine the...